Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC
The PALOMA-2 study showed monthly Rybrevant Faspro with Lazcluze achieved high response in untreated advanced EGFR-mutated NSCLC. Credit: Arif biswas/Shutterstock.com.
The PALOMA-2 study showed monthly Rybrevant Faspro with Lazcluze achieved high response in untreated advanced EGFR-mutated NSCLC. Credit: Arif biswas/Shutterstock.com.